Post-partum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus

Journal of Diabetes

Volumn 7, Issue 4, 2015, Pages 506-511

  Lappas, Martha ^a,b   Jinks, Debra ^b   Ugoni, Antony ^a   Louizos, Connie C J ^a,b   Permezel, Michael ^a,b   Georgiou, Harry M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

Diabetes; Gestational diabetes mellitus; Metabolic hormones type 2

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUERPERIUM; RISK ASSESSMENT; RISK FACTOR; BLOOD; PREGNANCY;

C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; FEMALE; GHRELIN; HUMANS; PREGNANCY;

EID: 84930382100     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12209     Document Type: Article

References (20)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med. 2007; 356: 213-215.
2. Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus: Clinical predictors and long-term risk of developing type 2 diabetes: A retrospective cohort study using survival analysis. Diabetes Care. 2007; 30: 878-883.
3. Ratner RE, Christophi CA, Metzger BE etal.; Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: Effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008; 93: 4774-4779.
4. Buchanan TA, Xiang AH, Peters RK etal. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002; 51: 2796-2803.
5. Akinci B, Celtik A, Yener S, Yesil S. Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertil Steril. 2010; 93: 1248-1254.
6. Bo S, Monge L, Macchetta C etal. Prior gestational hyperglycemia: A long-term predictor of the metabolic syndrome. J Endocrinol Invest. 2004; 27: 629-635.
7. Ekelund M, Shaat N, Almgren P etal. Genetic prediction of postpartum diabetes in women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2012; 97: 394-398.
8. Kwak SH, Choi SH, Kim K etal. Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. Diabetologia. 2013; 56: 2556-2563.
9. Genuth S, Alberti KG, Bennett P etal.; Expert Committee on The Diagnosis Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160-3167.
10. Damm P, Kuhl C, Hornnes P, Molsted-Pedersen L. A longitudinal study of plasma insulin and glucagon in women with previous gestational diabetes. Diabetes Care. 1995; 18: 654-665.
11. Hsu C-N, Chang C-H, Lin Y-S, Lin J-W, Caffrey JL. Association of serum C-peptide concentrations with cancer mortality risk in pre-diabetes or undiagnosed diabetes. PLoS ONE. 2013; 8: e55625.
12. Min JY, Min KB. Serum C-peptide levels and risk of death among adults without diabetes mellitus. Can Med Assoc J. 2013; 185: E402-408.
13. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003; 52: 2546-2553.
14. Poykko S, Ukkola O, Kauma H, Savolainen MJ, Kesaniemi YA. Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects. Diabetologia. 2003; 46: 455-458.
15. Bennett NR, Boyne MS, Cooper RS etal. Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. Clin Endocrinol (Oxf). 2009; 70: 408-414.
16. Vartiainen J, Rajala U, Jokelainen J, Keinanen-Kiukaanniemi S, Kesaniemi YA, Ukkola O. Serum ghrelin and the prediction of the development of impaired glucose regulation and Type 2 diabetes in middle-aged subjects. J Endocrinol Invest. 2010; 33: 496-500.
17. Barazzoni R, Zanetti M, Ferreira C etal. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab. 2007; 92: 3935-3940.
18. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005; 115: 485-491.
19. Bo S, Valpreda S, Menato G etal. Should we consider gestational diabetes a vascular risk factor? Atherosclerosis. 2007; 194: e72-79.
20. Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes Care. 2007; 30 (Suppl. 2): S246-250.